SG Americas Securities LLC Grows Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

SG Americas Securities LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7,876.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 132,960 shares of the biopharmaceutical company's stock after buying an additional 131,293 shares during the period. SG Americas Securities LLC owned approximately 0.10% of Alnylam Pharmaceuticals worth $35,902,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Truist Financial Corp boosted its stake in shares of Alnylam Pharmaceuticals by 136.6% in the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after purchasing an additional 2,539 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after buying an additional 8,462 shares during the last quarter. Ieq Capital LLC raised its holdings in Alnylam Pharmaceuticals by 825.5% in the 4th quarter. Ieq Capital LLC now owns 38,806 shares of the biopharmaceutical company's stock valued at $9,131,000 after buying an additional 34,613 shares during the last quarter. IFP Advisors Inc raised its holdings in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 47 shares during the last quarter. Finally, Brighton Jones LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $243,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the transaction, the chief executive officer now directly owns 48,948 shares in the company, valued at $14,899,281.72. This trade represents a 39.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ALNY shares. Chardan Capital raised their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a report on Monday, March 31st. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, Stifel Nicolaus raised their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded down $3.88 on Wednesday, hitting $298.58. The stock had a trading volume of 454,983 shares, compared to its average volume of 930,235. Alnylam Pharmaceuticals, Inc. has a 52-week low of $152.30 and a 52-week high of $313.79. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock has a market cap of $38.93 billion, a price-to-earnings ratio of -137.59 and a beta of 0.22. The business's 50-day simple moving average is $266.98 and its two-hundred day simple moving average is $258.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals's revenue was up 20.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.16) earnings per share. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.